Vistagen Therapeutics Share Price Today

Vistagen gets FDA nod on LSAS endpoint for fasedienol Phase 3 trial

FDA provided constructive feedback on using LSAS as the primary endpoint for fasedienol in Phase 3 SAD trials. Vistagen will incorporate interim assessments using eDiaries and qualitative patient surveys into the study design. The agency recognized fasedienol's safety profile and potential to benefit a broad population of SAD patients. Vistagen plans to submit a revised protocol to the FDA focusing on overall rather than just acute treatment.

Vistagen shares rise 58% on fasedienol efficacy data in severe anxiety

Vistagen Therapeutics shares rose 58.55% to $0.39 following positive preliminary data from its PALISADE-4 Phase 3 trial open-label extension. Exploratory data presented at Psych Congress 2026 highlights a potential efficacy signal for fasedienol in patients with very severe social anxiety disorder (LSAS >=95). In the extension trial, 65% of subjects experienced a 20-point or greater improvement on the Liebowitz Social Anxiety Scale at month four. Analysts caution against overinterpreting open-label data due to lack of placebo control, noting uncertainty regarding FDA requirements for future pivotal studies.

Vistagen appoints Douglas J. Williamson to board of directors

Vistagen Therapeutics Inc. has appointed Douglas J. Williamson, MD, to its Board of Directors. Williamson brings deep experience in neuroscience drug development from roles at QurAlis, Acadia Pharmaceuticals, and Eli Lilly. His appointment coincides with the advancement of Vistagen’s Phase 3 candidate fasedienol for social anxiety disorder.

Vistagen shifts strategy after Phase 3 trial miss

Vistagen Inc. reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol failed to meet its primary endpoint for social anxiety disorder in the overall population, though a post-hoc analysis showed benefit in patients with very severe symptoms. The company plans to pivot its strategy toward long-term treatment and engage with the FDA on a new registrational pathway. With $45.4 million in cash, Vistagen expects to fund operations into 2027.

VistaGen Q4 sales beat estimates as FY26 loss widens

VistaGen Therapeutics announced quarterly sales of $465,000, exceeding analyst expectations, while the loss per share narrowed to $(0.37) against estimates. For the fiscal year ended March 31, 2026, the company reported a net loss of $69.7 million, driven by a rise in R&D expenses to $55.0 million. The company also provided updates on its PALISADE-4 Phase 3 trial and leadership appointments.